An acquired autoactivating mutation with a V617F amino-acid substitution in the JAK2 tyrosine kinase is frequently found in BCR/ABL-negative myeloproliferative disorders (MPD). Hypermethylation of CpG islands within gene promoter regions is associated with transcriptional inactivation and represents an important mechanism of gene silencing in the pathogenesis of hematopoietic malignancies. In this study, we determined the DNA methylation status of 13 cancer-related genes in the context of JAK2 mutations in 39 patients with MPD. Genes analyzed for hypermethylation were SOCS-1, SHP-1, E-cadherin, MGMT, TIMP-2, TIMP-3, p15, p16, p73, DAPK1, RASSF1A, RARb2 and hMLH1. We found at least one hypermethylated gene in 15/39 MPD patient specimens, and in 6/39 samples aberrant methylation of the negative cytokine regulator SOCS-1 was present. The JAK2V617F mutation was found in 21/39 patients as determined by allele-specific polymerase chain reaction. Hypermethylation of SOCS-1 was observed in 3/21 patients with an autoactivating JAK2 mutation and in 3/18 patients with wild-type JAK2. Our results suggest that epigenetic inactivation of SOCS-1 may be a complementary mechanism to the JAK2V617F mutation in the pathogenesis of MPD that leads to dysregulation of JAK-STAT signal transduction and thus contributes to growth factor hypersensitivity.
Introduction
BCR/ABL-negative myeloproliferative disorders (MPD) traditionally comprise essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis with myeloid metaplasia (MMM). In patients with MPD, hematopoiesis is monoclonal and thought to be initiated by a genetically transformed mutant stem cell clone that retains the capacity to differentiate into multiple cell lineages. 1, 2 Karyotypic abnormalities can be detected in 10-15% of patients with MPD, and the most frequent aberrations are trisomies of chromosomes 8 and 9 as well as chromosomal deletions of 5q, 11q, 13q, 20q and Y. [3] [4] [5] Erythroid progenitor cells from patients with PV are capable of forming colonies in the absence of erythropoietin, and a hypersensitivity to different growth factors has been described in ET, PV and MMM. [6] [7] [8] As a consequence, an abnormality in a signaling component downstream of the growth factor receptors was suggested. 9 Using a candidate gene approach and a highthroughput DNA sequencing technique, the discovery of a gainof-function mutation in the gene coding for the Janus kinase (JAK) 2 protein in MPD has been an important step forward to understand the molecular basis of this group of diseases. [10] [11] [12] JAK2 is a cytoplasmic tyrosine kinase with a key role in signal transduction for multiple hematopoietic growth factor receptors. [13] [14] [15] In the JAK2 gene, a G4T mutation leads to a Val617Phe substitution in the JH2 domain of the JAK2 protein and is responsible for constitutive signaling of this molecule with subsequent hypersensitivity to hematopoietic growth factors. This somatic point mutation could be detected in 23-57% of patients with ET, 65-97% with PV and 35-57% with MMM. 16, 17 The modified JAK2 sequence was found in granulocytes from patients with MPD and also in myeloid cells derived from CD34-positive cells, but not in T cells. 11, 12 In MMM, the JAK2V617F mutation has been shown to correlate with poorer overall survival, 18 and in ET patients, there was an association with higher hemoglobin values and an increased risk of thrombosis. 19 PV patients with a homozygous mutational status for JAK2 had higher hemoglobin levels, an increased incidence of pruritus and a higher degree of bone marrow fibrosis compared to patients with a heterozygous JAK2 mutation. 20 The physiological regulation of JAK2 activity is under the control of a group of proteins termed suppressors of cytokine signaling (SOCS). Additionally, SH2-containing domain tyrosine phosphatases such as SHP-1 are also involved in negative regulation of the JAK/Signal transducer and activator of transcription (STAT) pathway. Loss-of-function owing to biallelic mutation of SOCS-1 in a lymphoma cell line has been demonstrated to contribute to increased JAK2 phosphorylation activity without overexpression at the protein level. 21 Silencing of SOCS-1 in association with CpG island hypermethylation has been reported in various hematopoietic malignancies such as multiple myeloma and acute myeloid leukemia (AML). 22, 23 Furthermore, dysregulation of the JAK/STAT pathway by epigenetic inactivation of SHP-1 has been described in hematological malignancies. [24] [25] [26] There is increasing evidence that, in addition to genetic alterations, epigenetic processes play a major role in tumorigenesis. [27] [28] [29] The inheritance of information based on the expression levels is known as epigenetics, as opposed to genetics which refers to information transmitted on the basis of gene sequence. Aberrant methylation of CpG islands near gene promoter regions is the most widely studied epigenetic abnormality in human malignancies and has been established as an important mechanism for gene silencing. The binding of protein complexes consisting of methyl CpG-binding proteins, transcriptional corepressors, chromatin remodeling proteins and histone deacetylases to hypermethylated DNA regions results in a transcriptionally repressive chromatin state. 30 This epigenetic event thus acts as an alternative mechanism to mutations and deletions to disrupt the function of cancer-related genes. Additionally, there is increasing evidence for potential interactions between genetic and epigenetic events in the pathogenesis of malignant tumors. 31, 32 Aberrant CpG island methylation in MPD has been reported for abelson (ABL), p14, p15, p16 and retinoic acid receptor beta2 (RARb2). [33] [34] [35] [36] RARb2 promoter hypermethylation with concurrently decreased expression of the gene at the RNA level was found in 16/18 MMM patients. 36 ABL has been shown to be methylated in a minor percentage of samples from patients with ET, PV and MMM. 33 Hypermethylation of the promoter region of p15 and p16 was not detected in the chronic phase of MMM but only at leukemic transformation. 34 No aberrant methylation has been reported for transforming growth factor beta, retinoblastoma protein, MutL protein homologue 1 (hMLH1), MutS protein homologue 2, adenomatosis polyposis coli and deathassociated protein kinase 1 (DAPK1) in samples from patients with MPD. 35 To gain additional information about the relevance of epigenetic changes in MPD in the context of the newly described JAK2-activating mutation, we analyzed the methylation patterns of 13 cancer-related genes by methylation-specific polymerase chain reaction (MSP) in bone marrow (BM) or peripheral blood (PB) cells from patients with ET, PV and MMM. Genes analyzed for hypermethylation were the negative regulator of cytokine signaling SOCS-1, the SH2 domaincontaining tyrosine phosphatase SHP-1, the adhesion molecule E-cadherin (E-cad), the DNA repair genes O 6 -methylguanine DNA transferase (MGMT) and hMLH1, the tissue inhibitors of matrix metalloproteinases TIMP-2 and TIMP-3, the cell cycle regulators p15, p16 and p73, RARb2 and the apoptosis-related factors DAPK1 and RAS effector homologue 1 (RASSF1A). For all these genes, the relevance of gene silencing in association with CpG island hypermethylation has been described previously. 27, [37] [38] [39] Additionally, the JAK2V617F mutational status was analyzed by allele-specific polymerase chain reaction (PCR) and direct sequencing.
Materials and methods

Human tissue samples
After informed consent was given, 28 PB and 11 BM specimens were obtained during routine clinical assessment of 39 adult patients with MPD in chronic phase (10 at diagnosis and 29 during follow-up) without evidence for leukemic transformation. The collection of patient samples for analysis of genetic and epigenetic changes was approved by the local ethics committee. DNA extraction was performed from unselected cells from BM, when available, or PB. Diagnosis was made in accordance with standard criteria. [40] [41] [42] Seven patients were classified as ET, nine as PV and 23 as MMM. Median age was 64 years, with 23 females and 16 males. Median disease duration at sampling was 71 months (range, 1-300). Median laboratory blood parameters were as follows: White blood cell 14.6 G/l (range, 1.7-47.7 G/l), hemoglobin 146 g/l (range, 77-153 g/l), platelets 446 G/l (range, 14-1234 G/l), lactate dehydrogenase (LDH) 466 U/l (range, 169-1600 U/I) and peripheral blast cell percentage 2% (range, 0-10%).
PB samples from healthy volunteers were collected to serve as controls.
MSP
Genomic DNA was isolated from primary cells using standard methods. Approximately 1 mg of DNA was sodium bisulfitemodified and subjected to MSP. 43 This assay entails the initial modification of DNA by sodium bisulfite, converting all unmethylated cytosines to uracils, but leaving the methylated cytosines unchanged, followed by subsequent amplification with primers specific for methylated vs unmethylated DNA. A purification of BM or PB samples based on membrane antigen expression was not performed because of the great sensitivity of the MSP technique with a detection limit of approximately 0.1% methylated DNA present in an otherwise unmethylated sample. 43 Primer sequences and reaction conditions for MSP have been described previously. [44] [45] [46] For every MSP reaction, in vitro methylated DNA (IVD) 47 and normal PB from healthy volunteers served as controls. PCR products were separated on 2.5% agarose gels and visualized by ethidium bromide staining.
JAK2 mutation analysis
The mutational status of the JAK2 gene was assessed using two different techniques. For sequencing analysis, genomic DNA was amplified by PCR with a starting amount of 25 ng DNA. The PCR mix contained 10 Â buffer, MgCl 2 1.5 mM, dNTPs 0.8 mM each and 2.5 U Taq polymerase (Invitrogen, Carlsbad, CA, USA). Primers as described by Steensma et al. 48 with a forward primer sequence 5 0 -TGCTGAAAGTAGGAGAAAGTGCAT-3 0 and a reverse primer sequence 5 0 -TCCTACAGTGTTTTCAGTTT CAA-3 0 were used. PCR cycling parameters were a denaturation step at 941C for 2 min followed by 35 cycles at 941C for 30 s, 521C for 40 s, 721C for 40 s and a final extension step of 2 min at 721C. Successful amplification was confirmed on 2% agarose gels. PCR products were cleaned with the Qiaquick PCR purification kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Fluorescent BigDye chemistry sequencing was performed using the same primers as for amplification and analyzed using an ABI Prism 3100 genetic analyzer (Applied Biosystems, Foster city, CA, USA). Sequence analysis was performed on the basis of the GenBank accession number NM_004972.
For allele-specific PCR, 80 ng of genomic DNA was amplified in a 34-cycle PCR with an annealing temperature of 601C. Primers and reaction conditions used were as described by Baxter et al. 10 After amplification, the presence of a JAK2V617F mutation was assessed on 2% agarose gels after ethidium bromide staining. In a dilution series of DNA from a patient with a homozygous JAK2V617F mutation with normal DNA, the sensitivity of the PCR could be shown to be at least 1/64. Undiluted and diluted (1/32) DNA from a patient with homozygous JAK2V617F mutation was used as a positive control, and DNA from a healthy donor as a negative control for every PCR reaction.
Statistical analysis
Diagnostic clinical and laboratory parameters were compared between patients with the mutated or unmutated form of the JAK2 gene and between patients with or without aberrant CpG island methylation. Data were analyzed using w 2 test for nominal data and Mann-Whitney test for ordinal data.
Results
Methylation analysis of cancer-related genes
We analyzed the methylation status of 13 cancer-related genes by MSP in 39 samples from patients with ET, PV or MMM.
These genes were chosen based upon well-characterized methylation patterns in other hematopoietic malignancies and solid tumors as described above. Representative MSP results are shown in Figure 1 . At least one methylated CpG island was detected in 15/39 patient samples. The incidence of aberrant methylation for ET, PV and MMM is summarized in Table 1 .
JAK2 mutation analysis
After direct sequencing, a G4T conversion corresponding to the JAK2V617F mutation could be detected in 15 MPD samples. Three of the 15 samples demonstrated a 100% signal for the G4T mutation and were considered to be homozygous. A mixed G and T signal was obtained in 12 samples indicating either a heterozygous JAK2 mutation or a homozygous mutation with a background of non-malignant cells present in the sample.
Using allele-specific PCR, 21/39 samples (53.8%) showed a signal corresponding to the JAK2 G4T mutation. Two of the seven ET samples and seven of the nine PV patients had a JAK2 mutation. Among the MMM samples, 12/23 carried a JAK2 mutation. Representative results of the allele-specific PCR are shown in Figure 2 . All sequencing results indicating the presence of a JAK2V617F mutation were confirmed by allelespecific PCR. However, using allele-specific PCR, we were able to detect six additional samples to carry a mutated JAK2 gene. These data indicate a greater sensitivity of allele-specific PCR compared to direct sequencing when applied to unselected cells from PB or BM. Therefore, the results of the allele-specific PCR were used for further analysis.
Correlations with clinical parameters
No statistically significant correlations were demonstrated between methylation patterns and the clinical parameters age, sex, leukocyte count, peripheral blast cell count, red blood cells, platelet count, LDH, spleen size, degree of BM fibrosis or disease duration. In the MMM patient group, there was a trend toward an association with higher age in patients with a JAK2V617F mutation (72 vs 56 years, P ¼ 0.003).
Epigenetic and genetic changes
We then compared the results of JAK2 mutation analysis with CpG island methylation patterns. The low frequency of methylation at loci other than SOCS-1 prevented meaningful comparisons, but samples with a JAK2V617F mutation had hypermethylation of MGMT, p15 and three times SOCS-1. The bold letters highlight the hypermethylated genes. Figure 2 Representative JAK2 mutation analysis of MPD patient samples by allele-specific PCR. The 203 bp PCR product is specific for the mutant allele, whereas the 364 bp product amplifying both mutant and wild-type alleles serves as an internal PCR control. DNA from a healthy donor (PB) was used as a negative control. DNA from a patient with a homozygous JAK2V617F mutation served as a positive control (1222a: undiluted; 1222b: diluted 1/32). M ¼ DNA ladder. Patient samples 1120, 1122 and 1372 carry a JAK2 mutation.
Epigenetic alterations in MPD E Jost et al
However, distinct patterns were observed in methylation of SOCS-1 and mutation of JAK2. Methylation of SOCS-1 was not found in any of the three patients with homozygous JAK2 mutations, but was present in three of the other 18 patients with a JAK2 mutation, and in three of the 18 patients with wild-type JAK2. Among the 18 patients without a JAK2V617F mutation, nine samples showed hypermethylation of at least one gene. We detected CpG island methylation for SOCS-1 (three samples), p15 (three samples), DAPK1 (two samples), E-cad (two samples) and TIMP-2 (one sample) respectively. Fifteen samples with a JAK2V617F mutation had no aberrant CpG island methylation. A summary of concomitant SOCS-1 hypermethylation and JAK2 mutation is given in Table 2 .
Discussion
Most data on the pathogenesis of BCR/ABL-negative MPD are based on cytogenetic analysis, 4,49 mutation screening, 11,12 loss of heterozygosity analysis 36 or gene expression studies (Jones LC, Tefferi A, Wachsman W, Hofmann WK, Koeffler HP, Blood 2001; 98: 626; abstract). Limited information is available about epigenetic disturbances in MPD, and so far no study has analyzed DNA methylation patterns in the context of genetic changes of JAK2. In our cohort of 39 MPD patients, we found that aberrant methylation of most genes examined was uncommon. Pathways affected by epigenetic changes included cell cycle regulation (p15, p16 and p73), cell adhesion (E-cad and TIMP-2), DNA repair (MGMT), cytokine signaling (SOCS-1) and apoptosis (DAPK1). However, compared to the methylation patterns in other hematopoietic malignancies, aberrant CpG island methylation of these candidate genes was less frequent in BCR/ABL-negative MPD. 38 Notably, the frequency of p15 hypermethylation was lower than in other myeloid malignancies. 50 Aberrant methylation of the cell cycle regulator p15 has been reported only in MMM in leukemic phase. 34 One patient with p15 methylation had 10% BM blasts at the time of the study, supporting the hypothesis that p15 may contribute to leukemic transformation of MMM. We found CpG island methylation of the p15 gene also in 3/7 patients with ET without evidence for leukemic transformation, a result not reported previously. We detected aberrant DAPK1 methylation in two patients with MPD, whereas this gene was not shown to be hypermethylated in a previous study. 35 There was no hypermethylation of hMLH1 in concordance with other published data. 34, 35 One striking difference from the published literature is our discordant frequency of RARb2 methylation, which was reported to be methylated in 16 of 18 patients with MMM, 36 whereas we did not observe methylation of the promoter region in 39 samples (23 of which were MMM). As the region analyzed by MSP was identical, the differences can possibly be explained by a higher cycle number in the PCR reaction (39 vs 35 cycles in our study) or by the CD34 selection performed by Jones and coworkers, enhancing potentially the sensitivity of the reaction. However, the sensitivity of MSP is reported to be 1/1000, 43 and therefore even a minor population of cells with CpG island hypermethylation can be detected by this technique. Additionally, the lack of CD34 selection did not lead to difficulties in detecting methylation of SOCS-1 and other genes in our study.
To the best of our knowledge, no data have been published about aberrant CpG island hypermethylation of RASSF1A, p73, E-cad, TIMP-2, SHP-1 and SOCS-1 in MPD. Methylation of TIMP-2, MGMT, DAPK1, p16, E-cad and p73 was infrequent. SOCS-1 and p73 were concomitantly methylated in one patient after a disease history of 19 years, whereas only SOCS-1 was methylated in this patient 16 years after diagnosis, suggesting the accumulation of methylation events with disease duration. Of interest will be the collection of samples during the disease course of patients for several years and the correlation of methylation profiles with disease progression.
SOCS-1 was the most frequently hypermethylated gene in our patient group, but SOCS-1 CpG island methylation occurred less frequently in MPD than in myelodysplastic syndromes or AML. 23, 39, 44, 51 The SOCS-1 protein is a negative regulator of cell signaling and may also contribute to higher JAK2 activity when its function is abolished. 52 The importance of the loss-offunction of SOCS-1 by mutation with consecutive higher activity of JAK2 has been described in malignant lymphomas. 21 An alternative or complementary mechanism for aberrant JAK2 activity caused by the V617F mutation may be an increased activity of JAK2 owing to methylation-associated silencing of SOCS-1. Interestingly, all three samples with homozygous JAK2V617F mutation did not carry a hypermethylated SOCS-1 CpG island. SOCS-1 is also a negative regulator of other tyrosine kinases such as KIT and ABL, and both may be involved in the pathogenesis of human cancer. 53 Further support for the important role of SOCS-1 in myelopoiesis is provided by the frequent epigenetic inactivation of SOCS-1 in other hematopoietic malignancies 22, 23 and the occurrence of lethal MPD in SOCS-1 deficient mice 3 weeks after birth. 54 Downregulation of SHP-1 by promoter methylation as a mechanism for a higher JAK2 activity in MPD is unlikely, as none of the samples in our cohort showed aberrant SHP-1 hypermethylation.
The incidence of the V617F mutation of JAK2 in our study is in accordance with previous reports on ET, PV and MMM. 12, 16, 17 Until now, little data are available about correlations between clinical parameters and JAK2V617F mutational status. We found that among MMM patients those with a mutated JAK2 tyrosine kinase were older than those with wild-type JAK2. This association has not been described previously, but must be considered carefully owing to the small patient number. A poorer survival of patients with a JAK2 mutation in MMM has been reported in a recent study. 55 However, owing to limited follow-up data, we could not assess the prognostic impact of epigenetic changes and JAK2 mutational status in our patient collective.
The fundamental role of the JAK/STAT pathway in normal and malignant hematopoiesis has been established previously. [13] [14] [15] As JAK2-activating mutations occur only in about half of the patients, other molecular alterations have been postulated in the development of MPD. 56 We hypothesize that additional mechanisms such as epigenetic changes may contribute to the pathogenesis of MPD, especially regarding the well-described hypersensitivity to hematopoietic growth factors. As mutations in the JAK2 gene occurred simultaneously with CpG island methylation of the SOCS-1 gene, this suggests that genetic and epigenetic alterations may cooperate in the pathogenesis of Table 2 Results for concomitant JAK2 mutation and SOCS-1 hypermethylation in patients with ET, PV and MMM (U ¼ unmethylated, M ¼ methylated)
PV (n ¼ 9) MMM (n ¼ 23) and lung cancer 31 Further studies analyzing a larger number of primary patient samples will be necessary to further elucidate the possible role of SOCS-1 hypermethylation in MPD and the interaction of this and other epigenetic modifications with JAK2 activity.
Tyrosine kinases have emerged as a promising target for the treatment of diseases with proven genetic alterations in corresponding pathways, as for example imatinib in chronic myelogenous leukemia (CML). 59 Inhibitors of JAK2 such as the agent AG490 are not considered to be specific for the V617F mutated form of the protein, 60, 61 and clinical experience with JAK2 tyrosine kinase inhibitors is lacking at the moment. Epigenetic aberrations can be modulated by the demethylating agents 5-aza-2 0 -deoxycytidine and 5-azacytidine. Both drugs have been found to be of interest in the treatment of AML, myelodysplastic syndromes and blast crisis of CML. 62 Clinical studies using agents targeting the epigenome in MPD patients may be worthwhile, especially in the advanced stage of leukemic transformation.
